The medical sector recently witnessed a major breakthrough with the unveiling of a novel antibody treatment designed for migraine prevention. The so-called therapy has recently completed Phase III human clinical trials with remarkably positive outcomes, leading to anticipations with regard to the treatment for world’s one of the most debilitating diseases.
For the uninitiated, migraine currently affects close to 15 percent of the global population and is claimed to be one of the topmost ailments that lack effective medical treatments. The new approach comes on the heels of innovating a targeted treatment for the disease which unfortunately yet aptly is referred to as a major loophole in medical research.
Reportedly, the treatment revolves around the mechanism of blocking CGRP (calcitonin gene-related peptide) receptors in the brain. For the record, CGRP, as per reliable studies, is claimed to significantly trigger pain in migraine patients.
As per reliable sources, three of the four drugs targeting the above mechanism are already undergoing Phase III human clinical trials. Erenumab is seemingly the first drug that completely testified Phase III results. The drug as per the evaluation study STRIVE has been claimed to have reported positive outcomes pertaining to its effectiveness as well as safety. Studies describe the patients who received full dosage of Erenumab to have reported a 50 percent drop in their monthly migraine attacks which is quite high against the 26.6 percent drop reported by Placebo group.
Apparently, Fremanezumab, another monoclonal antibody, also reported successful outcomes in Phase III trials with close to 40 percent of the subjects reporting their migraine days per month reducing by half.
Though there have been no insights on the financials of these monoclonal antibody treatments, experts believe the cost of these drugs to be on the higher side, at least in the initial phase.